Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Future Directions in Multiple Myeloma

June 21st 2017

Emerging Agents for Multiple Myeloma

June 21st 2017

CAR T-Cell Therapy for Multiple Myeloma

June 21st 2017

Immunotherapy for Multiple Myeloma

June 21st 2017

Sequencing Therapies in Multiple Myeloma

June 21st 2017

Continuing IMiD Therapy after Myeloma Relapse

June 21st 2017

Antibodies for Relapsed/ Refractory Multiple Myeloma

June 21st 2017

Maintenance Therapy for Multiple Myeloma

June 21st 2017

Optimal Timing for Transplantation in Myeloma

June 21st 2017

Risk Stratification for Myeloma

June 21st 2017

MRD Negativity in Multiple Myeloma

June 21st 2017

Goals of Therapy for Symptomatic Myeloma

June 21st 2017

Dr. Usmani Discusses CAR T-Cell Therapy in Multiple Myeloma

June 19th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses CAR T-cell therapy in multiple myeloma.

FDA Accepts Denosumab sBLA for Multiple Myeloma

June 19th 2017

The FDA has accepted a supplemental biologics license application for the use of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.

FDA Approves Third Daratumumab Triplet for Myeloma

June 16th 2017

The FDA has approved daratumumab for use in combination with pomalidomide and dexamethasone for patients with multiple myeloma who have received at least 2 prior therapies, including a proteasome inhibitor and lenalidomide.

Dr. Jagannath on Mechanism of Action of Selinexor in Myeloma

June 16th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the mechanism of action of selinexor and its efficacy in multiple myeloma and other tumor types.

Merck Pauses Enrollment in 2 Pembrolizumab Myeloma Trials

June 13th 2017

Merck announced that it is postponing enrollment in the phase III KEYNOTE-183 and KEYNOTE-185 trials because of deaths in patients with multiple myeloma assigned to pembrolizumab (Keytruda), the company's blockbuster anti-PD-1 therapy.

Dr. Jakubowiak on Phase I Daratumumab Regimens in Newly Diagnosed Multiple Myeloma

June 12th 2017

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, The University of Chicago Medicine, discusses a phase I study of daratumumab (Darzalex) in combination with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma.

Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma

June 9th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

BCMA CAR T-Cell Therapy Yields High Remission Rate in Multiple Myeloma

June 6th 2017

Early results from a Chinese study showed that 33 of 35 patients (94%) with relapsed or refractory multiple myeloma experienced clinical remission after treatment with chimeric antigen receptor T cells targeting B-cell maturation protein.